Tumor tissues vary considerably in their microenvironment, and the existence of other cell types can influence the ability of the immune system to infiltrate and attack tumor cells. As promising new therapies evolve, there is an increasing need to identify cancer immunotherapy biomarkers to guide their appropriate application.
NGS can provide careful analysis of the cancer genome, and efficiently assess the tumor microenvironment as a real-time, highly sensitive monitor of immune marker expression in response to tumor growth or treatment. NGS analysis can be used to characterize the immune cell repertoire, identify various cell populations in the microenvironment, and comprehensively quantify gene expression of thousands of targets simultaneously.
RNA analysis may help to identify aspects of the tumor microenvironment that can influence the effectiveness of checkpoint immunotherapies, such as inductive and inhibitory cytokines, and local recruitment of other cell types that can inhibit the T-cell response.
Studies of epigenetic alterations in cancer, such as aberrant methylation and altered transcription factor binding, can provide insight into important tumorigenic pathways. NGS and microarray technologies can detect altered methylation and other epigenetic patterns in cancer.Learn More About Cancer Epigenetics
Single-cell sequencing proves invaluable in detecting intracellular communication in tumors.Read Interview
RNA-Seq and HLA typing using NGS are powering the Immatics target discovery platform.Read Interview
High-throughput sequencing has shown remarkable utility in cancer and immunology research, as well as in the development of individualized immunotherapy.Read Review
A spatial genomics approach to defining the microenvironment landscape of molecular subtypes of metastatic prostate cancer reveals patterns that may predict the utility of immune-based therapies.View Webinar
In this webinar, Dr. Holger Heyn of the Barcelona Institute of Science and Technology discusses efforts to combine single cell and spatial transcriptomics to generate a comprehensive tumor immune atlas across cancer types.View Webinar
Cancer researchers need simple-to-use bioinformatics applications to gain insights from tumor microenvironment studies and other complex genomic data. BaseSpace Correlation Engine allows biologists and researchers to analyze their data in the greater biological context of a highly curated multi-omic datasets with push button analytics requiring no specialized bioinformatics skills. The retrospective analysis of clinical trial data can help inform future cancer research and drug development programs.
Learn more about BaseSpace Correlation Engine.
Illumina offers several library preparation and sequencing options with access to data analysis options for tumor microenvironment analysis. Streamlined workflows and flexible kit configurations accommodate multiple study designs.
Approximately 90% of the world’s sequencing data are generated using Illumina sequencing by synthesis (SBS) chemistry.*
Click on the below to view products for each workflow step.
Illumina DNA Prep with Enrichment uses a fast, user-friendly workflow. On-bead tagmentation chemistry is combined with a simplified, single hybridization protocol to reduce total workflow time.TruSeq DNA Exome
TruSeq DNA Exome is a cost-effective library preparation and exome enrichment solution.TruSeq RNA Exome
The TruSeq RNA Exome library prep kit provides a low-cost solution for analyzing human RNA isolated from limited or low-quality samples, including FFPE.
Transcriptome profiling of hundreds to tens of thousands of single cells in a single experiment.TruSight Oncology 500
Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.
Flexible configurations that support up to 12 exomes per run.NextSeq 1000 & 2000 Systems
These systems are redesigned from the ground up to maximize future proofing, offering sequencing power for high-throughput applications.
Flexibility and unprecedented throughput for virtually any genome, sequencing method, and scale of project.
*Data calculations on file, Illumina, Inc, 2015.